Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Bundamedik TbkISX:BMHS -0.99%75 EV-to-EBIT is 44.86 as of Sep. 09, 2026, which is 45% above its 10-year median of 30.86. GuruFocus rates ISX:BMHS with a GF Score™ of 75/100 and a GF Value™ of Rp267.27 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 476 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks worse than 86.34% on this metric.
The historical rank and industry rank for PT Bundamedik Tbk's EV-to-EBIT or its related term are showing as below:
ISX:BMHS'
s EV-to-EBIT Range Over the Past 10 Years
Min: 12.98 Med: 30.86 Max: 47.29
Current: 44.86
During the past 8 years, the highest EV-to-EBIT of PT Bundamedik Tbk was 47.29. The lowest was 12.98. And the median was 30.86.
ISX:BMHS's EV-to-EBIT is ranked worse than 86.34% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 15.155
vs ISX:BMHS: 44.86
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PT Bundamedik Tbk's Enterprise Value for the quarter that ended in Jun. 2026 was Rp3,222,717 Mil.
PT Bundamedik Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp76,250 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk EV-to-EBIT Related Terms
PT Bundamedik Tbk EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's EV-to-EBIT falls into.
PT Bundamedik Tbk's current Enterprise Value is Rp3,420,596 Mil.
PT Bundamedik Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp76,250 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a EV-to-EBIT of 44.86 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Bundamedik Tbk and its competitors. This is 45% above median its historical median of 30.86. Over the past decade, PT Bundamedik Tbk's EV-to-EBIT has ranged from 12.98 to 47.29. According to the industry distribution chart, PT Bundamedik Tbk ranks #411 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 86.3%.
Is PT Bundamedik Tbk's EV-to-EBIT too high?
PT Bundamedik Tbk's current EV-to-EBIT of 44.86 is 45% above median its 10-year median of 30.86. Over the past 10 years, this metric has ranged from a low of 12.98 to a high of 47.29. The Healthcare Providers & Services industry median EV-to-EBIT is 15.16. PT Bundamedik Tbk's value of 44.86 is 196% above this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #411 out of 476 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Bundamedik Tbk has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #411 out of 476 companies for EV-to-EBIT. This places PT Bundamedik Tbk in the lower half of its industry. The industry median EV-to-EBIT is 15.16. PT Bundamedik Tbk's value of 44.86 is 196% above this benchmark. Historically, PT Bundamedik Tbk's own EV-to-EBIT has ranged from 12.98 to 47.29 over the past decade. While the company's 10-year median is 30.86 vs. the industry median of 15.16, PT Bundamedik Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.16, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current EV-to-EBIT of 44.86 is 196% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current EV-to-EBIT is 44.86, which is 45% above median its own 10-year median of 30.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp267.27, compared to a current price of Rp200.00 — trading 25.2% below its estimated fair value. The current EV-to-EBIT is 44.86, which is 45% above median its 10-year median of 30.86 and 196% above the Healthcare Providers & Services industry median of 15.16. PT Bundamedik Tbk's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current EV-to-EBIT is 44.86 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp200.00 is trading 25.2% below its estimated GF Value™ of Rp267.27.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
EV-to-EBIT: 44.86 (45% above median its 10-year median of 30.86)
GF Value™: Rp267.27 vs. price of Rp200.00 (25.2% below fair value)
Industry Position: 196% above the Healthcare Providers & Services median (#411 of 476)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
75GF Score
Get the complete analysis for ISX:BMHS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
